FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2769162239> ?p ?o ?g. }

• W2769162239 abstract "78 Background: Advanced cancers remain a major cause of mortality in Nigeria. Participation in clinical trials (PCTs) and palliative end-of-life care (PEOLC) are two approaches to incurable cancer management in the developed nations but these have been less adopted in Nigeria. This study set out to determine patients’ preferred approach between PCTs and PEOLC for management of advanced cancers in Nigeria. Methods: A survey of 120 advanced cancer patients was conducted using a questionnaire with 5-point Likert scale, variables of interest included demographic information, knowledge and perception about PCTs and PEOLC. Results: Majority of the patients (84%) agree PCTs is an option in management of incurable cancer but just about half accept it is beneficial and will improve their QOL, as against PEOLC, where all the patients considered it an option and deem it beneficial; with 99% and 98% respectively agreeing it will enhance their QOL and that of family members. About 56% believe PCTs carries a risk of burdensome interventions and 52% increased hospital stay at EOL while 47% are of the opinion it will increase cost of care with 45% stating it will lead to increased ICU death. Sixty-nine percent (69%) and 63% respectively agree PCTs increases the suffering of patients and family members while 43% believe it carries a net negative risk-benefit profile, nevertheless, 83% are ready to overlook the risk of PCTs for possible therapeutic benefit while for 87%, the primary motivation for PCTs is personal cure. Majority (58%) believe PCTs does not improve quality of dying/death contrary to PEOLC where 88% believe it would improve the quality of dying/death. Overall, by direct comparison 78%:13% prefer PEOL to PCTs; {X 2 (p-value), 40.26(0.001)}. Conclusions: Both modalities are acceptable to advanced cancer patients but the study reveals several ethical issues with PCTs including risk of burdensome interventions, suffering of patients, therapeutic misconception and misperception of curability. A major determinant to accepting PEOL is its positive impact on patients’ QOL. Concerted efforts are needed to significantly enhance access of PEOLC to cancer patients." @default.
• W2769162239 created "2017-12-04" @default.
• W2769162239 creator A5007551696 @default.
• W2769162239 creator A5023229624 @default.
• W2769162239 date "2017-11-01" @default.
• W2769162239 modified "2023-09-27" @default.
• W2769162239 title "Patients' perspectives on participation in clinical trials and palliative end-of-life care for management of advanced cancers in Nigeria." @default.
• W2769162239 doi "https://doi.org/10.1200/jco.2017.35.31_suppl.78" @default.
• W2769162239 hasPublicationYear "2017" @default.
• W2769162239 type Work @default.
• W2769162239 sameAs 2769162239 @default.
• W2769162239 citedByCount "0" @default.
• W2769162239 crossrefType "journal-article" @default.
• W2769162239 hasAuthorship W2769162239A5007551696 @default.
• W2769162239 hasAuthorship W2769162239A5023229624 @default.
• W2769162239 hasConcept C126322002 @default.
• W2769162239 hasConcept C143998085 @default.
• W2769162239 hasConcept C159110408 @default.
• W2769162239 hasConcept C177713679 @default.
• W2769162239 hasConcept C2780879335 @default.
• W2769162239 hasConcept C2994186709 @default.
• W2769162239 hasConcept C512399662 @default.
• W2769162239 hasConcept C535046627 @default.
• W2769162239 hasConcept C71924100 @default.
• W2769162239 hasConceptScore W2769162239C126322002 @default.
• W2769162239 hasConceptScore W2769162239C143998085 @default.
• W2769162239 hasConceptScore W2769162239C159110408 @default.
• W2769162239 hasConceptScore W2769162239C177713679 @default.
• W2769162239 hasConceptScore W2769162239C2780879335 @default.
• W2769162239 hasConceptScore W2769162239C2994186709 @default.
• W2769162239 hasConceptScore W2769162239C512399662 @default.
• W2769162239 hasConceptScore W2769162239C535046627 @default.
• W2769162239 hasConceptScore W2769162239C71924100 @default.
• W2769162239 hasLocation W27691622391 @default.
• W2769162239 hasOpenAccess W2769162239 @default.
• W2769162239 hasPrimaryLocation W27691622391 @default.
• W2769162239 hasRelatedWork W1549579822 @default.
• W2769162239 hasRelatedWork W2104255363 @default.
• W2769162239 hasRelatedWork W2136039338 @default.
• W2769162239 hasRelatedWork W2159249088 @default.
• W2769162239 hasRelatedWork W2185604410 @default.
• W2769162239 hasRelatedWork W2336805566 @default.
• W2769162239 hasRelatedWork W2344588387 @default.
• W2769162239 hasRelatedWork W2506636261 @default.
• W2769162239 hasRelatedWork W2591365482 @default.
• W2769162239 hasRelatedWork W2599841307 @default.
• W2769162239 hasRelatedWork W2620271176 @default.
• W2769162239 hasRelatedWork W2756235166 @default.
• W2769162239 hasRelatedWork W2761823489 @default.
• W2769162239 hasRelatedWork W2795341699 @default.
• W2769162239 hasRelatedWork W2802275062 @default.
• W2769162239 hasRelatedWork W2900184939 @default.
• W2769162239 hasRelatedWork W2981113667 @default.
• W2769162239 hasRelatedWork W3030333016 @default.
• W2769162239 hasRelatedWork W3202289902 @default.
• W2769162239 hasRelatedWork W2789212938 @default.
• W2769162239 isParatext "false" @default.
• W2769162239 isRetracted "false" @default.
• W2769162239 magId "2769162239" @default.
• W2769162239 workType "article" @default.